GlassScriptPhysician profile
Kerline Marcelin
NPI 1134151749
$5,040.93
in general payments reported to CMS, 2019-2025
19 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $900 · 2020: $815 · 2021: $693 · 2022: $742 · 2023: $641 · 2024: $833 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,890.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,478.83 | 2019-2025 | Simbrinza, Clareon, Eysuvis |
| Sight Sciences, INC. | $960.68 | 2020-2024 | Omni Surgical System |
| Merz North America, INC. | $522.20 | 2022-2023 | Xeomin |
| Allergan, INC. | $402.72 | 2020-2022 | |
| New World Medical,INC. | $391.57 | 2019 | |
| Abbvie INC. | $378.47 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $257.32 | 2024-2025 | Envista Mx60 Iol, Xiidra, Miebo |
| Harrow Eye, LLC | $158.34 | 2024 | Vevye |
| Oyster Point Pharma, INC. | $100.28 | 2023-2024 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $82.34 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $66.75 | 2019-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $49.43 | 2023 | Tecnis Simplicity |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $47.14 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $40.13 | 2024 | Xdemvy |
| Galderma Laboratories, L.P. | $34.31 | 2023-2025 | Dysport |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ivantis, INC | $19.21 | 2021 | |
| Dompe US, INC. | $17.27 | 2021 | |
| Aerie Pharmaceuticals, INC. | $14.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerline Marcelin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.